Should I Buy NCSM? NCSM 2026 Analysis

Should You Buy NCS Multistage Holdings Inc (NCSM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

38.670

1 Day change

1.55%

52 Week Range

53.690

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: momentum is weakening (bearish MACD) and the probabilistic trend skews negative over the next week/month.
Price is below the key pivot (38.992) and has nearby downside room toward S1 (36.881) if support fails.
Insider activity is a major red flag: insiders are selling, with selling up 118.77% over the last month.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.168) and expanding lower, suggesting bearish momentum building rather than stabilizing.
RSI: RSI(6) at 36.92 is weak (near oversold-ish) but still labeled neutral here—more consistent with a soft/down tape than a strong reversal signal.
Moving averages: Converging moving averages indicate consolidation; with MACD weakening, this consolidation is currently tilting bearish.
Levels to watch: Current price 38.32 is below Pivot 38.992.
- Support: S1 36.881 (then S2 35.577)
- Resistance: R1 41.102 (then R2 42.406)
Pattern-based odds: Similar-pattern projection implies ~-2.67% over the next week and ~-2.47% over the next month (near-term bias down).

Positive Catalysts

if buyers step in.

Neutral/Negative Catalysts

- Insiders are selling aggressively: selling activity increased 118.77% over the last month.
- Profitability is trending down despite revenue growth (net income, EPS, and gross margin all declined YoY).
- Bearish momentum signal: MACD histogram negative and worsening.
- No news/catalysts in the past week to justify a sudden upside re-rating.
- Similar-pattern projection points to mild downside over 1-week and 1-month horizons.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 46.538M, +5.75% YoY (top-line growth intact).
Net income: 3.808M, -8.17% YoY (earnings contraction).
EPS: 1.37, -14.37% YoY (per-share profitability weakening).
Gross margin: 38.42%, down 1.56 YoY (margin pressure).
Overall read: Growing sales but deteriorating margins/earnings—this is not the kind of trend that typically supports aggressive buying without a clear catalyst.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so recent Wall Street revisions cannot be verified here.
Practical takeaway given available data: absent visible analyst support and with insiders selling plus weakening technical momentum, the pro case is limited to revenue growth and potential support-level bounce; the con case (profit/margin erosion + bearish momentum) currently dominates.

Analyst Rating

Wall Street analysts forecast NCSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCSM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold